These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38157568)
21. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439 [TBL] [Abstract][Full Text] [Related]
22. The Impact of Poorly Differentiated Histology on Immunotherapy in Advanced Gastrointestinal Cancers. Draper A; Jung EH; Cao Y; Atallah RP; Switchenko J; Kane S; Guadagno J; Jones AT; Brutcher E; Alese OB Oncology; 2023; 101(4):213-223. PubMed ID: 36626879 [TBL] [Abstract][Full Text] [Related]
23. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability. Moreau M; Alouani E; Flecchia C; Falcoz A; Gallois C; Auclin E; André T; Cohen R; Hollebecque A; Turpin A; Pernot S; Masson T; Di Fiore F; Dutherge M; Mazard T; Hautefeuille V; Van Laethem JL; De la Fouchardière C; Perkins G; Ben-Abdelghani M; Sclafani F; Aparicio T; Kim S; Vernerey D; Taieb J; Guimbaud R; Tougeron D Eur J Cancer; 2024 May; 202():114033. PubMed ID: 38537314 [TBL] [Abstract][Full Text] [Related]
24. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271 [TBL] [Abstract][Full Text] [Related]
25. Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study. Hulst L; Cappuyns S; Peeters F; Vulsteke F; Van Herpe F; Van Cutsem E; Dekervel J Clin Colorectal Cancer; 2024 Sep; 23(3):230-237.e1. PubMed ID: 39097473 [TBL] [Abstract][Full Text] [Related]
26. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ratovomanana T; Nicolle R; Cohen R; Diehl A; Siret A; Letourneur Q; Buhard O; Perrier A; Guillerm E; Coulet F; Cervera P; Benusiglio P; Labrèche K; Colle R; Collura A; Despras E; Le Rouzic P; Renaud F; Cros J; Alentorn A; Touat M; Ayadi M; Bourgoin P; Prunier C; Tournigand C; Fouchardière C; Tougeron D; Jonchère V; Bennouna J; de Reynies A; Fléjou JF; Svrcek M; André T; Duval A Ann Oncol; 2023 Aug; 34(8):703-713. PubMed ID: 37269904 [TBL] [Abstract][Full Text] [Related]
27. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431 [TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series. Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555 [TBL] [Abstract][Full Text] [Related]
29. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France. Roset M; Amonkar M; Patel R; Lara N; Kothari S Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060 [TBL] [Abstract][Full Text] [Related]
30. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Colle R; Lonardi S; Cachanado M; Overman MJ; Elez E; Fakih M; Corti F; Jayachandran P; Svrcek M; Dardenne A; Cervantes B; Duval A; Cohen R; Pietrantonio F; André T Oncologist; 2023 Sep; 28(9):771-779. PubMed ID: 37023721 [TBL] [Abstract][Full Text] [Related]
31. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358 [TBL] [Abstract][Full Text] [Related]
32. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636 [TBL] [Abstract][Full Text] [Related]
33. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers. Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245 [TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y Front Immunol; 2022; 13():795972. PubMed ID: 35371084 [TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer. Yoshino T; Andre T; Kim TW; Yong WP; Shiu KK; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Alcaide-Garcia J; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Le DT; Adachi N; Fogelman D; Marinello P; Diaz LA Cancer Sci; 2023 Mar; 114(3):1026-1036. PubMed ID: 36369901 [TBL] [Abstract][Full Text] [Related]
36. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727 [TBL] [Abstract][Full Text] [Related]
37. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer. Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470 [TBL] [Abstract][Full Text] [Related]
38. Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. Margalit O; Stemmer A; Chapin WJ; Shacham-Shmueli E; Kopetz S; Andre T; Overman MJ; Pietrantonio F; Boursi B Eur J Cancer; 2024 Nov; 212():114336. PubMed ID: 39316932 [TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Le DT; Diaz LA; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil BH; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Élez E; Al-Batran SE; Boland PM; Cui Y; Leconte P; Marinello P; André T Eur J Cancer; 2023 Jun; 186():185-195. PubMed ID: 37141828 [TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. Fucà G; Corti F; Ambrosini M; Intini R; Salati M; Fenocchio E; Manca P; Manai C; Daniel F; Raimondi A; Morano F; Corallo S; Prisciandaro M; Spallanzani A; Quarà V; Belli C; Vaiani M; Curigliano G; Cremolini C; De Braud F; Di Bartolomeo M; Zagonel V; Lonardi S; Pietrantonio F J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849927 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]